Cargando…
Cerebrovascular Accidents Associated with Sorafenib in Hepatocellular Carcinoma
Sorafenib is an oral angiogenetic multikinase inhibitor approved in the treatment of renal and hepatocellular carcinoma. Bleeding and venous thrombotic events have been described with angiogenetic agents but cerebrovascular accidents are rarely reported. We report two cases of patients with hepatoce...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Hindawi Publishing Corporation
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113260/ https://www.ncbi.nlm.nih.gov/pubmed/21687621 http://dx.doi.org/10.1155/2011/616080 |